Published in Hum Pathol on December 01, 1984
Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer (2006) 3.23
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One (2007) 2.77
Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol (2000) 1.93
Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J (1989) 1.84
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol (2009) 1.71
Tumour progression and the nature of cancer. Br J Cancer (1991) 1.69
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A (1986) 1.54
Melanoma genetics and the development of rational therapeutics. J Clin Invest (2005) 1.50
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Accuracy in clinically evaluating pigmented lesions. BMJ (1989) 1.44
Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis (2003) 1.39
Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet (1986) 1.39
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res (2009) 1.34
msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation. Proc Natl Acad Sci U S A (1996) 1.27
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Trans Am Ophthalmol Soc (2000) 1.22
Study of Nevi in Children (SONIC): baseline findings and predictors of nevus count. Am J Epidemiol (2008) 1.21
Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle (2008) 1.20
Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol (1991) 1.20
Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol (2009) 1.19
Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol (1992) 1.17
Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol (1997) 1.16
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene (2011) 1.15
Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 1.14
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am J Pathol (1993) 1.13
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med (1993) 1.13
Nucleolar organiser regions in pathology. Br J Cancer (1992) 1.12
Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol (1994) 1.11
Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol (2012) 1.09
Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci U S A (1993) 1.09
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet (1993) 1.08
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol (1994) 1.07
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol (2012) 1.07
Melanocyte transformation associated with substrate adhesion impediment. Neoplasia (2006) 1.06
Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin Cancer Res (2006) 1.05
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res (2010) 1.03
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. Mol Pathol (1999) 1.00
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med (1988) 1.00
Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A (1988) 1.00
Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome Ip36. Am J Hum Genet (1990) 1.00
Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 1.00
Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res (2011) 0.98
Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol (2000) 0.97
Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol (1990) 0.97
Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo) (2011) 0.97
Genetic pathways to melanoma tumorigenesis. J Clin Pathol (2004) 0.93
Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. Br J Cancer (1994) 0.92
Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn (2002) 0.92
Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol (1995) 0.92
The radial growth phase of malignant melanoma: multi-phase modelling, numerical simulations and linear stability analysis. J R Soc Interface (2010) 0.92
NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One (2013) 0.90
Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol (2005) 0.90
Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi. J Clin Pathol (2005) 0.90
Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice. Proc Natl Acad Sci U S A (1993) 0.90
Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression. Proc Natl Acad Sci U S A (1995) 0.89
Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol (2009) 0.87
Lessons learned from studies of the development of early melanoma. Int J Clin Oncol (2005) 0.86
Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy. J Invest Dermatol (2014) 0.85
Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv (2013) 0.84
Induction of different morphologic features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu, and E1a oncogenes. Am J Pathol (1991) 0.84
Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol (2007) 0.83
Melanoma risk factors and atypical moles. West J Med (1994) 0.83
Sun-protective behaviors in populations at high risk for skin cancer. Psychol Res Behav Manag (2013) 0.83
Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol (1995) 0.82
Genetics of melanocytic nevi. Pigment Cell Melanoma Res (2015) 0.81
The epidemiology, prevention, and detection of melanoma. Ochsner J (2010) 0.81
ACP best practice no 162. The histological reporting of melanoma. Association of Clinical Pathologists. J Clin Pathol (2000) 0.81
Molecular biology and respiratory disease. 3. Evaluation of nucleolar organiser regions in pulmonary pathology. Thorax (1990) 0.81
The flow cytometry of melanocytic skin lesions. Br J Cancer (1988) 0.81
Clonal dynamics of progressive neoplastic transformation. Proc Natl Acad Sci U S A (1999) 0.80
Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy. Proc Natl Acad Sci U S A (1997) 0.80
Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families. J Am Acad Dermatol (2011) 0.79
Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract (2011) 0.79
Variability in melanoma metalloproteinase expression profiling. J Biomol Tech (2010) 0.79
Risk factors for malignant melanoma in white and non-white/non-African American populations: the multiethnic cohort. Cancer Prev Res (Phila) (2012) 0.79
Mechanical properties of growing melanocytic nevi and the progression to melanoma. PLoS One (2014) 0.78
A putative marker for human melanoma. A monoclonal antibody derived from the melanoma gene in the Xiphophorus melanoma model. Am J Pathol (1993) 0.77
CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity. PLoS One (2015) 0.77
Genome-wide analysis of gene and protein expression of dysplastic naevus cells. J Skin Cancer (2012) 0.76
Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers (Basel) (2015) 0.76
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer (2006) 0.76
Expression of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of MMP (TIMP)-1 in conjunctival melanomas and clinical implications. Jpn J Ophthalmol (2010) 0.76
Survival from melanoma of the skin in England and Wales up to 2001. Br J Cancer (2008) 0.76
Morphometric and ultrastructural analyses of melanocytes, nevus cells, and melanoma cells. Arch Dermatol Res (1987) 0.75
Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: utilization in design of syngeneic immunotherapy models. Proc Natl Acad Sci U S A (1997) 0.75
Evidence for autosomal dominance and pleiotropy of the cutaneous malignant melanoma (CMM)/Dysplastic nevus (DN) gene. Am J Hum Genet (1987) 0.75
Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. Indian J Surg (2012) 0.75
The growth pattern of transplanted normal and nodular hepatocytes. Histochem Cell Biol (2011) 0.75
"Mitogenicity"-the latest and mosthilarious episode in the slapstick comedy of melanoma management. Dermatol Pract Concept (2012) 0.75
Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. Methods Mol Biol (2015) 0.75
Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index. Arch Dermatol Res (1992) 0.75
Depletion of p42.3 gene inhibits proliferation and invasion in melanoma cells. J Cancer Res Clin Oncol (2017) 0.75
Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene (2017) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
THE CLINICAL EVALUATION OF AUREOMYCIN. J Clin Invest (1949) 3.60
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol (1978) 2.81
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst (1998) 2.53
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet (2005) 2.13
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
Solid tumors after chronic lymphocytic leukemia. Blood (2001) 2.01
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med (1991) 1.95
The developmental biology of primary human malignant melanomas. Semin Oncol (1975) 1.92
Premarital sex, schoolgirl pregnancy, and school quality in rural Kenya. Stud Fam Plann (2001) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA (1978) 1.74
The dynamics of a heroin addiction epidemic. Science (1973) 1.74
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Melanoma of unknown primary site: presentation, treatment, and prognosis--a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer (1997) 1.57
Action spectrum for retinal injury from near-ultraviolet radiation in the aphakic monkey. Am J Ophthalmol (1982) 1.56
Amyl nitrite may alter T lymphocytes in homosexual men. Lancet (1982) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Incidence of Kaposi's sarcoma and mycosis fungoides in the United States including Puerto Rico, 1973-81. J Natl Cancer Inst (1984) 1.54
Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. J Natl Cancer Inst (1978) 1.53
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Smoking and movement disorders in psychiatric patients. Biol Psychiatry (1991) 1.50
Primary malignant melanoma of the urinary bladder. Cancer (1976) 1.48
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet (1986) 1.39
Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 1.38
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
Observations on Cogan's microcystic dystrophy of the corneal epithelium. Trans Am Ophthalmol Soc (1965) 1.35
How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol (1986) 1.34
Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet (1986) 1.34
Malignant melanoma in renal-transplant recipients. Lancet (1981) 1.33
The nature of retinal radiation damage: dependence on wavelength, power level and exposure time. Vision Res (1980) 1.33
Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet (1982) 1.31
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med (1982) 1.29
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
A fine-structure study of the human epidermal melanosome complex and its acid phosphatase activity. J Ultrastruct Res (1968) 1.26
Familial and sporadic Hodgkin's disease associated with occupational wood exposure. Lancet (1978) 1.26
Proliferation, differentiation, and cytogenetics of chronic leukemic B lymphocytes cultured with mitomycin-treated normal cells. Blood (1981) 1.25